BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01 Other Events.
On April2, 2017, BeiGene,Ltd. (the Company) issued a press
release announcing clinical data from the Phase 1b dose-expansion
clinical trial of BGB-283 that was presented in an oral
presentation at the 2017 American Association for Cancer Research
(AACR) Annual Meeting held in Washington, D.C. on April2,
2017.The full text of the Companys press release is filed as
Exhibit99.1 to this Current Report on Form8-K and is incorporated
herein by reference.
Item9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued on April2, 2017 |
About BEIGENE, LTD. (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers. BEIGENE, LTD. (NASDAQ:BGNE) Recent Trading Information
BEIGENE, LTD. (NASDAQ:BGNE) closed its last trading session up +0.24 at 36.85 with 99,911 shares trading hands.
